Our researchers have discovered that a gene called JMJD6 plays an important role in the most aggressive form of neuroblastoma. What’s more, they’ve developed a targeted treatment against it.
Findings just published by our researchers reveal that anticancer drug CBL0137, previously shown to be active against many different cancers, is also highly effective against MLL-rearranged leukaemia, including the most common type of infant leukaemia.
In research published this week, scientists have found that a therapy originally developed to treat Alzheimer’s Disease could hold promise for children with T-cell acute lymphoblastic leukaemia.
Our researchers have found a way to dramatically slow neuroblastoma growth, using a combination of drugs that starves cells of essential nutrients called polyamines.
Groundbreaking research from our Leukaemia Biology Program has revealed how acute lymphoblastic leukaemia can become resistant to a class of anti-cancer drugs called glucocorticoids.
Our researchers have developed a method to measure the amount of copper inside neuroblastoma tumours. Published in the journal Theranostics, it offers a potential tool for treating and monitoring neuroblastoma.
Research published this week shows that gold-coated nanoparticles can be used to detect tiny amounts of cancer-related molecules in blood.
Our scientists have found a way to rein in a cancer-causing gene called MYCN and slow down the growth of the childhood cancer neuroblastoma.
Our researchers have used a tiny drug delivery vehicle to kill neuroblastoma cells without harming normal tissues.
If doctors can reliably tell which children are most likely to get their leukaemia back, they can offer more intensive treatment options to prevent it.